COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

An Open-Label, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzuman (BTCT4465A) in Combination with Polatuzuman Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma

Protocol No
HOFFMANN-LAROCHE-GO40516
Principal Investigator
Nirav Shah
Phase
I/II
Summary
The purpose of this study is to: -Test the safety of mosunetuzumab at different dose levels when given in combination with polatuzumab vedotin and to find out what effects, good and/or bad, the study treatment has on DLBCL or FL and to determine the most effective and safe dose; this is the dose-finding phase (Phase Ib) -Find out what effects, good or bad, mosunetuzumab in combination with polatuzumab vedotin has on DLBCL, FL, or MCL; this is the expansion phase (Arms I, J, and K of Phase II). -Find out what effects, good or bad, mosunetuzumab in combination with polatuzumab vedotin has on DLBCL, compared with rituximab in combination with polatuzumab vedotin. This is the randomized (randomly assigned to treatment) phase (Arms L and M of Phase II)
Description
Mosunetuzuman (BTCT4465A) in Combination with Polatuzuman Vedotin in B-Cell Non-Hodgkin Lymphoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL